Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nilotinib-induced liver injury: A case report.

Medicine - 4 Sept 2020

Tan Youwen, Ye Yun, Zhou Xingbei

Abstract excerpt

INTRODUCTION: Nilotinib is a selective inhibitor of the BCR-ABL tyrosine kinase receptor and is used in the management of chronic myelogenous leukemia (CML). Nilotinib therapy at high doses is associated with elevated serum bilirubin levels. If the serum bilirubin level exceeds 3 times the upper limit of normal, the recommendation is to either adjust nilotinib dosage or temporarily discontinue the treatment....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Glucuronosyltransferase
Share to Hyperbilirubinemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mothers

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 32899072
DOI: 10.1097/MD.0000000000022061
PMCID: PMC7478446

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nilotinib-induced liver injury: A case report.PMID 32899072Read ↗

Late Occurrence of Hyperbilirubinemia and Renal Dysfunction During Nilotinib Treatment for an Elderly Chronic Myeloid Leukemia: A Case ReportSemantic proximity Read ↗

Osimertinib-related liver injury with successful osimertinib rechallenge: A case report.Semantic proximity Read ↗

Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.Semantic proximity Read ↗

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Semantic proximity Read ↗

Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.Semantic proximity Read ↗

Severe hepatotoxicity during treatment with capmatinib.Semantic proximity Read ↗

Drug-induced liver injury due to antibiotics.Semantic proximity Read ↗

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity Read ↗

Vorasidenib-Induced Acute Liver InjurySemantic proximity Read ↗

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.Semantic proximity Read ↗

Gilteritinib-induced severe immune-related enteritis: a possible case report.Semantic proximity Read ↗

Utility of Tissue Biopsy in Amoxicillin-Clavulanate induced Concomitant Hepatic Failure and Renal Failure: A Case ReportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.